Sourced, not guessed

Grants (11): NIH RePORTER, NSF Award Search, UKRI Gateway to Research (UK — covers MRC, EPSRC, ESRC, AHRC, STFC, BBSRC, NERC, and Innovate UK), USASpending.gov (all US federal agencies, not just NIH/ NSF), Australian Research Council, CORDIS (EU Horizon Europe), NWO (Netherlands), ANR (France), JSPS/KAKEN (Japan — Grant-in-Aid for Scientific Research), NHMRC (Australia — health/medical grants, via the ARDC registry), and a Foundation/Unfunded source (OniX's own proprietary/curated data), and more coming.

Publications (5): PubMed, OpenAlex, Crossref, Europe PMC, bioRxiv/medRxiv (preprints, not yet peer-reviewed).

Clinical Trials (1): ClinicalTrials.gov. (more coming)

Bonus context, shown in every report regardless of scope (3): Grants.gov (open opportunities to apply for), the OniX OnPoint Newsletter + PIVOT, Google News (hyperlinked headlines).

​

A note on API keys: every source above is a plain public API except three — OpenAlex, JSPS/KAKEN, and NHMRC each require your own free, self-serve registration key. All three are optional: the app runs fine without them, and any source with no key just gets skipped in that report with a clear note. Pasting a key in (and testing that it works) takes one click inside the app itself, no Terminal needed — see the Setup & Instructions download for the registration links.

Two data sources, selected per search:

- Espacenet / EPO Open Patent Services (worldwide) — roughly 100 patent offices. Requires a free EPO OPS Consumer Key/Secret (registration isn't instant — EPO reviews applications).

- USPTO Open Data Portal (US only) — requires a free USPTO ODP API key (instant, via a free USPTO.gov account + ID.me verification).

You'll need your own key(s) for whichever source(s) you plan to use — credentials are tied to your own account and request quota, never shared. See the Setup & Instructions download for how to get each one.

Beyond what the databases return: the report also tells you whether your technology area looks crowded with existing patents or relatively open, ranks each patent found by how relevant it actually is to your search, and includes a simple chart showing the types of assets and mechanisms of action that came up most often.

Direct sources: Pulls directly from the FDA's and CMS's own records: approval history, safety/adverse-event reports, recalls, and current labeling (Drugs@FDA and FAERS), FDA Orphan Drug Designation status, CMS's drug-pricing data, and a cross-reference against ClinicalTrials.gov.

Also checks for extra regulatory hurdles beyond standard FDA review — for example, DEA rules for controlled substances, NRC rules for radioactive drug ingredients, or USDA/EPA rules for veterinary and genetically modified products — so animal-health and veterinary questions are covered too, not just human drugs.

Direct sources: Human Protein Atlas (target expression), PubChem and ChEMBL (bioactivity/safety/toxicity), COCONUT (natural-product structures), UniProt (target/mechanism fallback when no curated mechanism exists), PubMed (literature snapshot), Google News (real-time).

Every candidate structural analog is also re-scored on your own machine, so every result lands on one consistent similarity scale — regardless of which database first surfaced it, and not just whatever ranking the original source happened to give it.

Folded in when you opt into those report sections: the full Competitive Analysis Agent source list above, the full Patent Agent source list above, and the full Regulatory Agent source list above — each contributing a condensed, asset-specific signal rather than a full duplicate report.

Planned: Grants.gov (26 federal agencies, independent agencies, and commissions - listed here), European Commission, UK Research and Innovation, Australian Government Research Grants Services, Japan Society for the Promotion of Science, and private-foundations funding.

Planned focus: pre-seed, seed, and Series A life sciences funding activity, tracked from the public activity of a curated starting list of venture funds and corporate venture arms actively investing at this stage, including (among others):

- Venture funds: ARCH Venture Partners, 5AM Ventures, F-Prime Capital, Deerfield Management, Polaris Partners, Sofinnova Investments, Versant Ventures, Lumina Venture Partners, Frazier Healthcare Partners, Canaan Partners.

- Corporate venture arms: Johnson & Johnson Innovation (JJDC), Pfizer Ventures, Novartis Venture Fund, Sanofi Ventures, M Ventures, Boehringer Ingelheim Venture Fund, AbbVie Ventures, Takeda Ventures, Novo Holdings, Leaps by Bayer.

This is a starting list, not a final one — expect it to grow once the Agent is actually built.